Balkrishna Acharya, Khandrika Lakshmipathi, Varshney Anurag
Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, India.
Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Haridwar, India.
Front Pharmacol. 2021 Apr 19;12:635510. doi: 10.3389/fphar.2021.635510. eCollection 2021.
The current Severe Acute Respiratory Syndrome disease caused by Coronavirus-2 (SARS-CoV-2) has been a serious strain on the healthcare infrastructure mainly due to the lack of a reliable treatment option. Alternate therapies aimed at symptomatic relief are currently prescribed along with artificial ventilation to relieve distress. Traditional medicine in the form of Ayurveda has been used since ancient times as a holistic treatment option rather than targeted therapy. The practice of Ayurveda has several potent herbal alternatives for chronic cough, inflammation, and respiratory distress which are often seen in the SARS-CoV-2 infection. In this study we have used the aqueous extracts of (willd.) Hook. f. and Thomson in the form of Giloy Ghanvati, as a means of treatment to the SARS-CoV-2 spike-protein induced disease phenotype in a humanized zebrafish model. The introduction of spike-protein in the swim bladder transplanted with human lung epithelial cells (A549), caused an infiltration of pro-inflammatory immune cells such as granulocytes and macrophages into the swim bladder. There was also an increased systemic damage as exemplified by renal tissue damage and increased behavioral fever in the disease induction group. These features were reversed in the treatment group, fed with three different dosages of Giloy Ghanvati. The resultant changes in the disease phenotype were comparable to the group that were given the reference compound, Dexamethasone. These findings correlated well with various phyto-compounds detected in the Giloy Ghanvati and their reported roles in the viral disease phenotype amelioration.
由新型冠状病毒 2（SARS-CoV-2）引起的当前严重急性呼吸综合征疾病，主要由于缺乏可靠的治疗方案，给医疗基础设施带来了沉重负担。目前除了使用人工通气缓解痛苦外，还会开具旨在缓解症状的替代疗法。阿育吠陀形式的传统医学自古以来就被用作一种整体治疗方案，而非靶向治疗。阿育吠陀疗法有几种有效的草药替代品，可用于治疗慢性咳嗽、炎症和呼吸窘迫，这些症状在 SARS-CoV-2 感染中很常见。在本研究中，我们使用了匙羹藤（学名： Gymnema sylvestre (Retz.) R. Br. ex Schult.）的水提取物，制成吉罗伊干药糖剂（Giloy Ghanvati），作为在人源化斑马鱼模型中治疗 SARS-CoV-2 刺突蛋白诱导的疾病表型的一种手段。在移植了人肺上皮细胞（A549）的鱼鳔中引入刺突蛋白，导致粒细胞和巨噬细胞等促炎免疫细胞浸润到鱼鳔中。疾病诱导组还出现了全身损伤加重的情况，如肾组织损伤和行为性发热增加。在喂食三种不同剂量吉罗伊干药糖剂的治疗组中，这些特征得到了逆转。疾病表型的最终变化与给予参考化合物地塞米松的组相当。这些发现与吉罗伊干药糖剂中检测到的各种植物化合物及其在改善病毒疾病表型方面的报道作用密切相关。
